| Code | CSB-RA023986MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Denosumab-bnht, specifically targeting TNFSF11 (Tumor Necrosis Factor Superfamily Member 11), also known as RANK ligand (RANKL). TNFSF11 is a critical cytokine that regulates bone metabolism by binding to its receptor RANK on osteoclast precursors, thereby promoting osteoclast differentiation, activation, and survival. This signaling pathway plays an essential role in bone resorption and remodeling. Dysregulation of TNFSF11 is implicated in various skeletal disorders, including osteoporosis, bone metastases, and giant cell tumor of bone, as well as in certain immune-mediated conditions where bone loss occurs.
Denosumab-bnht is a fully humanized IgG2 monoclonal antibody that functions by binding to and neutralizing TNFSF11, preventing its interaction with RANK and subsequently inhibiting osteoclast-mediated bone resorption. This biosimilar antibody provides researchers with a valuable tool for investigating RANKL-RANK signaling pathways, studying bone metabolism mechanisms, exploring skeletal disease pathogenesis, and evaluating potential therapeutic interventions in preclinical models.
There are currently no reviews for this product.